NTRK1 and cancer: NTRK gene fusions, prevalent across a variety of cancers, are recognized as a pan-cancer oncogenic factor.427–432 To combat these, the FDA has approved two SMIs, larotrectinib433 and entrectinib,434 and numerous other TRK inhibitors are currently under development.435–440 Despite their initial success, the development of acquired resistance has curtailed the efficacy of these treatments, highlighting the necessity for innovative therapeutic strategies.